Ken Griffin Eliem Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $618 Billion
- Q3 2025
Shares
4 transactions
Others Institutions Holding ELYM
# of Institutions
67Shares Held
44.3MCall Options Held
0Put Options Held
0-
Ra Capital Management, L.P. Boston, MA31.4MShares$129 Million2.22% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.32MShares$5.41 Million0.0% of portfolio
-
Affinity Asset Advisors, LLC New York, NY1.3MShares$5.34 Million0.62% of portfolio
-
Kynam Capital Management, LP Princeton, NJ1.03MShares$4.23 Million0.36% of portfolio
-
Tang Capital Management LLC San Diego, CA1MShares$4.11 Million0.19% of portfolio
About Eliem Therapeutics, Inc.
- Ticker ELYM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,567,700
- Market Cap $109M
- Description
- Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase II...